1. Health

Psoriasis Blog


Psoriasis Symptoms: His Versus Hers

Friday June 21, 2013

Does gender play a role in psoriasis? While the disease affects both women and men, new research suggests that men experience more severe symptoms compared to women. The study included 2,294 Swedish patients with moderate-to-severe psoriasis.

The study, published in PLOS One, is available in full for free here.

Is there a Link Between Body Weight and Psoriasis?

Friday June 21, 2013

Research from Northwestern University suggests there may be a connection, at least in young children. When researchers looked at 409 pediatric psoriasis patients, they found a correlation between plaque psoriasis, the most common form, and excess weight. This is worrisome because factors such as high body mass index (obesity), as well as high waist-to-height ratio, are potential predictors of future heart disease. Read more about the health risks related to childhood obesity here.

Further research into the impact of psoriasis on childhood body mass is underway.

Kim Kardashian Has Psoriasis

Friday September 16, 2011

Kim Kardashian

Recently revealed on the Keeping Up With the Kardashians TV show: Celebrity Kim Kardashian has psoriasis. She and her sister initially guessed it might be ringworm until a dermatologist diagnosed it correctly. Kim was shocked.

According to the National Psoriasis Foundation, Kardashian said "I'd heard of psoriasis before because my mom has always had it, but she didn't have red flaky dots all over her," says Kim, 30, about her psoriasis.

Read more to find out if psoriasis is generally considered a genetic disorder.

Safety Alert: Methotrexate Recall

Friday October 29, 2010

The FDA has issued a safety alert for some vials of methotrexate, which may contain small flakes of glass. Sandoz is recalling the following products:

Product : Methotrexate Injection, USP, 50mg/2mL
NDC Number : 66758-040-02 (10 vial pack) and 66758-040-01 (Individual vial)

Lot Number
Label Type
Exp Date
92395606 Parenta 12/2010
92760803 Parenta 2/2011
92965104 Parenta 3/2011
92965106 Parenta 3/2011
92965904 Parenta 4/2011
93255704 Parenta 6/2011
93502204 Parenta 7/2011
93635404 Parenta 8/2011
93681704 Parenta 8/2011
93794904 Sandoz 9/2011
95198604 Sandoz 10/2011
95357804 Sandoz 12/2011
95537704 Sandoz 1/2012
95987004 Sandoz 3/2012

Product : Methotrexate Injection, USP, 250mg/10mL
NDC Number : 66758-040-08 (10 vial pack) and 66758-040-07 (Individual vial)

Lot Number
Label Type
Exp Date
92395703 Parenta 12/2010
92760903 Parenta 2/2011
92965203 Parenta 3/2011
92966003 Parenta 4/2011
93255803 Parenta 6/2011
93502303 Parenta 7/2011
93635503 Parenta 8/2011
93795003 Sandoz 9/2011
95198703 Sandoz 10/2011
95357903 Sandoz 12/2011

If you have one of the affected vials, call the dedicated Methotrexate Recall Hotline at 1-888-896-4565 (staffed around the clock) or email Sandoz.methotrexaterecall@gencopharma.com. If you have already used some of the methotrexate and have experienced any side effects that you think might be related to the recall, contact your doctor right away.

Country singer LeAnn Rimes speaks out about psoriasis

Wednesday April 28, 2010

Country singer LeAnn Rimes has suffered from psoriasis since she was two-years-old. Her psoriasis got so bad, she started bleeding on stage during a performance.

Her battle with psoriasis is why she recently signed on to be the spokeswoman for the Stop Hiding Behind Psoriasis Campaign that is sponsored by the American Academy of Dermatology and National Psoriasis Foundation.

The campaign is urging people with psoriasis to pledge to get involved in their disease, including making a commitment to find a good dermatologist, find support and tell their story.

According to the campaign, almost 7 million Americans have psoriasis.

Stelara Gets the Green Light

Monday September 28, 2009

A new option in the fight against psoriasis -- Stelara (ustekinumab). The FDA -- after two long years of talks -- has approved the use of this drug for psoriasis patients who are candidates for phototherapy or systemic treatment, reports MedPage Today. It is to be used for moderate to severe cases. In trials, patients who followed the regimen recommended were able to achieve significantly clear skin for about a year. This is an injectible drug.  A few heads up before you talk to your doctor and seek Stelara -- use may cause the immunosupression, and you'll need a TB test before starting to use it.

Raptiva (efalizumab) Pulled From the Market

Monday April 13, 2009
Biologics are one of the treatment options available for psoriasis. However, psoriasis sufferers will now have to cope with one less option.

Raptiva (efalixumab), a well-know biologic, will no longer be available, according to a press release published by manufacturer Genentech last week.

Genentech is voluntarily pulling the drug from the market in the United States because of, "an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal disease of the central nervous system." This will occur in phases, so that doctors have time to safely transition patients to an alternative.

If you're on Raptiva, don't stop taking the medication on your own. Doing so may cause a flare-up, so be sure to contact your healthcare provider to determine your next best steps. Your doctor may recommend that you transition to another biologic psoriasis drug, such as Amevive, Enbrel, Humira or Remicade.

Psoriasis and the Risk of Diabetes

Sunday January 18, 2009
an article in the British Journal of Dermatology (Br J Dermatol. 2008;159(6):1331-1337) looked at the rate of new-onset diabetes developing in patients with psoriasis. They took their data from the UK -based General Practice Research Database. The Risk of developing diabetes was higher in those patients with psoriasis. The severity of the psoriasis was what related to the risk of diabetes, not the BMI (body mass index) which would have related it to obesity instead (another common finding in diabetes). Psoriasis is being looked at more and more as a marker or risk factor for many other serious conditions.

More on Psoriasis and Heart Disease

Sunday January 11, 2009
The current issue of the American Journal of Cardiology contains a consensus document by dermatologists and cardiologists regarding the increased risk of cardiovascular disease in patients with psoriasis. The relationship between heart disease and psoriasis has been noted since 1961. Large epidemiological studies done since then have added support to the idea that psoriasis patients are indeed at risk for heart disease.

The consensus statement recommends that two groups of psoriasis patients be evaluated for vascular disease: those with moderate to severe psoriasis; and those with mild psoriasis plus a recognized risk factor for vascular disease such as abdominal obesity or hypertension.

Psoriasis, Homocysteine and Heart Disease

Sunday January 11, 2009
A really interesting study from Turkey looked at serum homocysteine levels in patients with psoriasis. Elevated homocysteine levels are a recognized risk factor for heart disease. More recently, psoriasis itself has been proposed as an independent risk factor for heart disease. Two interesting finding from the study should be mentioned. Firstly, overally homocysteine levels did not differ significantly between psoriasis patients and controls. Second, and of possible clinical importance to patients is that homocysteine levels did correlate with the severity of psoriasis. Once conclusion that could possibly be raised by such data is that reducing the severity of psoriasis may in fact reduce the severity of heart disease. Although this has not been studied in and of itself, it may change the risk/benefit profiles of many treatments. The side effects of some psoriasis treatments may be more acceptable if in fact heart disease risk is also being mitigated.

©2014 About.com. All rights reserved.